Exelixis Submit Due Diligence Report for Cdc7 Inhibitor XL413 to BMS

Exelixis has submitted data to BMS on CDC7 inhibitor XL413. BMS has 30 days to decide whether it wants to select the compound for clinical development and commercialization.

Erbitux plus Irinotecan effective in Colorectal cancer

Newly publsihed data from the MABEL study shows Erbitux plus Irinotecan is effective in Colorectal cancer

Lilly to acquire ImClone

Eli Lilly has announced that it will acquire ImClone Systems through an all cash tender offer of $70.00 per share, or approximately $6.5 billion.

5 year data in Head and Neck cancer shows erbitux increases overall survival

Five year data presented at the American Society for Therapeutic Radiology and Oncology (ASTRO) Meeting show that erbitux (cetuximab), combined with radiation, increases overall survival in  patients with locally or regionally advanced squamous cell carcinoma of the head and neck (SCCHN).

Erbitux now available in Japan for Advanced Colorectal Cancer

ImClone Systems have announced that erbitux (cetuximab) has been commercially launched in Japan for use in treating patients with advanced or metastatic colorectal cancer.

Dasatinib effective in imatinib-resistant PDGFRA D842V mutant isoform

In vitro data suggests that Dasatinib may be effective against imatinib-resistant GIST PDGFRA D842V mutant isoforms

Erbitux continues to be effective in metastatic colorectal cancer

Data presented at the European of Medical Oncology (ESMO) show that Erbitux, plus FOLFIRI, continueds to show efficacy in patients with previously untreated metastatic colorectal cancer (mCRC).

Merck Serono submit Erbitux for NSCLC in Europe

Merck Serono has submitted an EMEA application for Erbitux (cetuximab) for use in the firstline treatment of epidermal growth factor receptor (EGFR) expressing, advanced or metastatic non-small cell lung cancer (NSCLC).

Erbitux improves first line Head and Neck Cancer Survival (NEJM)

Imclone and BMS have announced the publication of  Phase III results of Erbitux (cetuximab) plus platinum-based chemotherapy in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN).

ImClone submit sBLA for Erbitux in First-Line Head and Neck Cancer

ImClone Systems has submitted an sBLA to the US FDA to broaden the use of ERBITUX (cetuximab) to include first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.